Analysis of PAX8 immunohistochemistry in lung cancers: a meta-analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: In this meta-analysis, we aimed to evaluate the PAX8 immunohistochemical expressions in primary lung cancers and metastatic cancers to the lung. Methods: We identified and reviewed relevant articles from the PubMed databases. Ultimately, 18 articles were included in this meta-analysis. PAX8 expression rates were analyzed and compared between primary and metastatic lung cancers. Results: The PAX8 expression rate in primary lung cancers was 0.042 (95% confidence interval [CI], 0.025 to 0.071). PAX8 expression rates of small cell (0.129; 95% CI, 0.022 to 0.496) and non-small cell carcinomas of the lung (0.037; 95% CI, 0.022 to 0.061) were significantly different (p = .049 in a meta-regression test). However, the PAX8 expression rates of adenocarcinoma (0.013; 95% CI, 0.006 to 0.031) and squamous cell carcinoma (0.040; 95% CI, 0.016 to 0.097) were not significantly different. PAX8 expression rates of metastatic carcinomas to the lung varied, ranging from 1.8% to 94.9%. Metastatic carcinomas from the lung to other organs had a PAX8 expression rate of 6.3%. The PAX8 expression rates of metastatic carcinomas from the female genital organs, kidneys, and thyroid gland to the lung were higher than those of other metastatic carcinomas. Conclusions: Primary lung cancers had a low PAX8 expression rate regardless of tumor subtype. However, the PAX8 expression rates of metastatic carcinomas from the female genital organs, kidneys, and thyroid were significantly higher than those of primary lung cancers.
Abstract
Background: In this meta-analysis, we aimed to evaluate the PAX8 immunohistochemical expressions in primary lung cancers and metastatic cancers to the lung. Methods: We identified and reviewed relevant articles from the PubMed databases. Ultimately, 18 articles were included in this meta-analysis. PAX8 expression rates were analyzed and compared between primary and metastatic lung cancers. Results: The PAX8 expression rate in primary lung cancers was 0.042 (95% confidence interval [CI], 0.025 to 0.071). PAX8 expression rates of small cell (0.129; 95% CI, 0.022 to 0.496) and non-small cell carcinomas of the lung (0.037; 95% CI, 0.022 to 0.061) were significantly different (p = .049 in a meta-regression test). However, the PAX8 expression rates of adenocarcinoma (0.013; 95% CI, 0.006 to 0.031) and squamous cell carcinoma (0.040; 95% CI, 0.016 to 0.097) were not significantly different. PAX8 expression rates of metastatic carcinomas to the lung varied, ranging from 1.8% to 94.9%. Metastatic carcinomas from the lung to other organs had a PAX8 expression rate of 6.3%. The PAX8 expression rates of metastatic carcinomas from the female genital organs, kidneys, and thyroid gland to the lung were higher than those of other metastatic carcinomas. Conclusions: Primary lung cancers had a low PAX8 expression rate regardless of tumor subtype. However, the PAX8 expression rates of metastatic carcinomas from the female genital organs, kidneys, and thyroid were significantly higher than those of primary lung cancers.
참고문헌 (43)
- Travis WD, "WHO classification of tumours of the lung, pleura, thymus and heart" (2015), International Agency for Research on Cancer
- Brown AF, "Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung", Arch Pathol Lab Med, 137, pp.1274~1281 (2013)
- Travis WD, "Pathology of lung cancer", Clin Chest Med, 23, pp.65~81 (2002)
- Ye J, "Diagnostic utility of PAX8, TTF-1 and napsin A for discriminating metastatic carcinoma from primary adenocarcinoma of the lung", Biotech Histochem, 87, pp.30~34 (2012)
- Bishop JA, "Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma", Hum Pathol, 41, pp.20~25 (2010)
- Boggaram V, "Thyroid transcription factor-1 (TTF-1", Nkx2.1, Clin Sci (Lond), pp.2009, 116[DOI]
- Ye J, "Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung", Appl Immunohistochem Mol Morphol, 19, pp.313~317 (2011)
- Asirvatham JR, "Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma", Appl Immunohistochem Mol Morphol, 22, pp.372~376 (2014)
- Bi R, "ALK rearrangement : a high-frequency alteration in ovarian metastasis from lung adenocarcinoma", Diagn Pathol, 14, pp.96~ (2019)
- Bi Y, "Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin : A comparative study with their pulmonary counterparts", J Surg Oncol, 114, pp.697~702 (2016)
- El-Maqsoud NM, "The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas", Tumour Biol, 37, pp.3123~3134 (2016)
- Gailey MP, "Immunohistochemistry for the novel markers glypican 3, PAX8, and p40(DeltaNp63)in squamous cell and urothelial carcinoma", Am J Clin Pathol, 140, pp.872~880 (2013)
- Heidarpour M, "Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors", Adv Biomed Res, 3, pp.96~ (2014)
- Laury AR, "A comprehensive analysis of PAX8expression in human epithelial tumors", Am J Surg Pathol, 35, pp.816~826 (2011)
- Lotan TL, "Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma", Am J Surg Pathol, 33, pp.1037~1041 (2009)
- Mentrikoski MJ, "Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology : utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin", Appl Immunohistochem Mol Morphol, 22, pp.635~641 (2014)
- Nonaka D, "Diagnostic utility of thyroid transcription factors Pax8 and TTF-2(FoxE1)in thyroid epithelial neoplasms", Mod Pathol, 21, pp.192~200 (2008)
- Ozcan A, "PAX 8 expression in nonneoplastic tissues, primary tumors, and metastatic tumors : a comprehensive immunohistochemical study", Mod Pathol, 24, pp.751~764 (2011)
- Suzuki A, "Diagnostic significance of PAX8 in thyroid squamous cell carcinoma", Endocr J, 62, pp.991~995 (2015)
- recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin, "Appl Immunohistochem Mol Morphol", 2013, 59~63
- Tacha D, "Expression of PAX8 in normal and neoplastic tissues : a comprehensive immunohistochemical study", Appl Immunohistochem Mol Morphol, 19, pp.293~299 (2011)
- Toriyama A, "Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours : a comparison with polyclonal PAX8 antibody", Histopathology, 65, pp.465~472 (2014)
- Vidarsdottir H, "Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases", Hum Pathol, 84, pp.221~230 (2019)
- Weissferdt A, "Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1", Mod Pathol, 26, pp.1554~1560 (2013)
- Bowen NJ, "Emerging roles for PAX8in ovarian cancer and endosalpingeal development", Gynecol Oncol, 104, pp.331~337 (2007)
- Kobel M, "Ovarian carcinoma subtypes are different diseases : implications for biomarker studies", PLoS Med, 5, pp.e232~ (2008)
- Nonaka D, "Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas", Am J Surg Pathol, 32, pp.1566~1571 (2008)
- Tong GX, "Expression of PAX8in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?", Am J Surg Pathol, 32, pp.1380~1387 (2008)
- Tong GX, "Expression of PAX8 in normal and neoplastic renal tissues : an immunohistochemical study", Mod Pathol, 22, pp.1218~1227 (2009)
- Albadine R, "PAX8(+)", p63(-)immunostaining pattern in renal collecting duct carcinoma(CDC) : a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract, 2010, pp.34, 965~969
- Fabbro D, "Expression of thyroid-specific transcription factors TTF-1and PAX-8 in human thyroid neoplasms", Cancer Res, 54, pp.4744~4749 (1994)
- Fujiwara M, "PAX8discriminates ovarian metastases from adnexal tumors and other cutaneous metastases", J Cutan Pathol, 37, pp.938~943 (2010)
- Niu FY, "Distribution and prognosis of uncommon metastases from non-small cell lung cancer", BMC Cancer, 16, pp.149~ (2016)
- Mazzaferri EL, "Endocrine tumors", pp.278~333 (1993), Blackwell Scientific Publications Inc
- Lin JD, "Clinical and pathological characteristics of secondary thyroid cancer", Thyroid, 8, pp.149~153 (1998)
- Nakhjavani MK, "Metastasis to the thyroid gland : a report of 43 cases", Cancer, 79, pp.574~578 (1997)
- Kuhn E, "Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study", Mod Pathol, 32, pp.787~798 (2019)
- Colby T, "Tumors of the lower respiratory tract", pp.107~134 (1995), Armed Forces Institute of Pathology
- Miettinen M, "Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma", Hum Pathol, 31, pp.1139~1145 (2000)
- Rossi G, "Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements : a clinicopathologic and immunohistochemical study of 75 cases", Am J Surg Pathol, 27, pp.311~324 (2003)
- Moretti L, "N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas", Mod Pathol, 25, pp.231~236 (2012)
- Morgan EA, "PAX8and PAX5 are differentially expressed in B-cell and T-cell lymphomas", Histopathology, 62, pp.406~413 (2013)
- Lorenzo PI, "Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors", Histochem Cell Biol, 136, pp.595~607 (2011)